1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina; Bajaj, Anshika; Archer, Jacob; Reeves, Rebecca; Ngo, Lisa; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fuseri, Nicola... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina; Bajaj, Anshika; Archer, Jacob; Reeves, Rebecca; Ngo, Lisa; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fuseri, Nicola... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina C.; Bajaj, Anshika; Archer, Jacob F.; Reeves, Rebecca S.; Ngo, Lisa Y.; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fu... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. (9th November 2020) Authors: Dummer, Reinhard; Gyorki, David; Hyngstrom, John; Berger, Adam; Conry, Robert; Demidov, Lev; Chan, Edward; Radcliffe, Hoi-Shen; Faries, Mark; Ross, Merrick Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma. (9th November 2020) Authors: Dummer, Reinhard; Gyorki, David; Hyngstrom, John; Berger, Adam; Conry, Robert; Demidov, Lev; Chan, Edward; Radcliffe, Hoi-Shen; Faries, Mark; Ross, Merrick Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A458 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial. (10th December 2020) Authors: Puzanov, Igor; Chesney, Jason; Collichio, Frances; Singh, Parminder; Milhem, Mohammed; Glaspy, John; Hamid, Omid; Ross, Merrick; Friedlander, Philip; Garbe, Claus; Logan, Theodore; Hauschild, Axel; Lebbe, Celeste; Yi, Min; Snyder, Wendy; Mehnert, Janice Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial. (6th November 2014) Authors: Kaufman, Howard L; Andtbacka, Robert HI; Collichio, Frances A; Wolf, Michael; Li, Ai; Shilkrut, Mark; Puzanov, Igor; Ross, Merrick Journal: Journal for immunotherapy of cancer Issue: Volume 2(2014)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. (December 2018) Authors: Amaria, Rodabe; Reddy, Sangeetha; Tawbi, Hussein; Davies, Michael; Ross, Merrick; Glitza, Isabella; Cormier, Janice; Lewis, Carol; Hwu, Wen-Jen; Hanna, Ehab; Diab, Adi; Wong, Michael; Royal, Richard; Gross, Neil; Weber, Randal; Lai, Stephen; Ehlers, Richard; Blando, Jorge; Milton, Denái; Woodman,... Journal: Nature medicine Issue: Volume 24:Number 12(2018) Page Start: 1941 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Bilateral Breast Reconstruction With Profunda Artery Perforator Flaps and Immediate Implant Augmentation. Issue 1 (14th January 2020) Authors: Chu, Carrie K; DeFazio, Michael; Largo, Rene D; Ross, Merrick Journal: Aesthetic surgery journal Issue: Volume 2:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Issue 12 (13th July 2016) Authors: Andtbacka, Robert H. I.; Agarwala, Sanjiv S.; Ollila, David W.; Hallmeyer, Sigrun; Milhem, Mohammed; Amatruda, Thomas; Nemunaitis, John J.; Harrington, Kevin J.; Chen, Lisa; Shilkrut, Mark; Ross, Merrick; Kaufman, Howard L. Journal: Head & neck Issue: Volume 38:Issue 12(2016) Page Start: 1752 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗